Mechanism of<unk>  inhibition of CYP2D6. Pharmacodynamics<unk>  is the most potent and one of the most specific selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitors (SSRIs). It also binds to the allosteric site of the serotonin transporter, similarly, but less potently, than escitalopram.<unk>  also inhibits the reuptake of norepinephrine to a lesser extent (i (nM) SERT 0.07 - 0.2 NET 40 - 85 DAT 490 D2 7,700 5-HT1A 21,200 5-HT2A 6,300 5-HT2C 9,000 α1 1,000 - 2,700 α2 3,900 M1 72 H1 13,700 - 23,700 Pharmacokinetics<unk>  is well-absorbed following oral administration. It has an absolute bioavailability of about 50%, with evidence of a saturable first pass effect. When taken orally, it achieves maximum concentration in about 6–10 hours and reaches steady-state in 7–14 days.<unk>  exhibits significant interindividual variations in volume of distribution and clearance. Less than 2% of an oral dose is excreted in urine unchanged.<unk>  is a mechanism-based inhibitor of CYP2D6. Metabolism of<unk>  in humans.
Paroxetine
Atomoxetine
Dapoxetine
Citalopram
Reboxetine
Escitalopram
Duloxetine
Fluoxetine